Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors
Completed · Phase 1
Conditions studied: Metastatic Adenocarcinoma of the Colon or Rectum, Malignant Solid Tumors
In brief
The purpose of the study is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-MIF antibody in subjects with malignant solid tumors (Arm 1) and in subjects with metastatic adenocarcinoma of the colon or rectum (Arm 2).
Key facts
- Study ID
- NCT01765790
- Run by
- Baxalta now part of Shire
- People needed
- 68
- Starts
- 2012-06-14
- Expected to finish
- 2016-07-28
- Last updated by the study team
- 2021-05-05
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Scottsdale Healthcare — Scottsdale, Arizona, United States
- Florida Cancer Specialists / Sarah Cannon Research Institute — Sarasota, Florida, United States
- Department of Investigator Cancer Therapeutics, University of Texas, MD Anderson Cancer Center — Houston, Texas, United States
- Cancer Therapy and Research Center (CTRC), The University of Texas Health Science Center at San Antonio — San Antonio, Texas, United States
- Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg — Heidelberg, Germany
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.